Table 5

Effect of the timely empirical antifungal treatment (<12 hours) or delayed antifungal treatment (>12 hours) on positive (OC+) or negative (OC−) ocular candidiasis finding in relation with fluconazole or echinocandin treatment. In addition, association of the most common risk factors (presence of central venous catheter or abdominal malignancy) with positive or negative OC finding in relation with fluconazole or echinocandin treatment

Antifungal treatmentFluconazole
n (%)
Echinocandin
n (%)
OCOC+OC−OC+OC−
All Candida (n=101)20 (19.8)29 (28.7)12 (11.8)40 (39.6)
 Treatment delay <12 hours (n=68)14 (20.5)18 (26.4)9 (13.2)27 (39.7)
 Treatment delay >12 hours (n=29)4 (13.7)9 (31.0)3 (10.3)13 (44.8)
 Central venous catheter (n=57)15 (26.3)14 (24.5)6 (10.5)*22 (38.6)
 Abdominal malignancy (n=31)11 (35.4)7 (22.6)2 (6.5)*10 (32.2)
Candida albicans (n=73)17 (23.2)16 (21.9)12 (16.4)28 (38.3)
 Treatment delay <12 hours (n=48)12 (25.0)9 (18.8)9 (18.8)18 (37.6)
 Treatment delay >12 hours (n=22)3 (13.6)6 (27.2)3 (13.6)10 (45.4)
 Central venous catheter (n=43)15 (34.9)7 (16.2)6 (13.9)*15 (34.9)
 Abdominal malignancy (n=21)9 (42.9)4 (19.0)2 (9.5)6 (28.6)
Non-albicans (n=28)3 (10.7)13 (46.4)0 (0)12 (42.9)
 Treatment delay <12 hours (n=20)2 (10.0)9 (45.0)0 (0)9 (45.0)
 Treatment delay >12 hours (n=7)1 (14.2)3 (42.9)0 (0)3 (42.9)
 Central venous catheter (n=15)1 (6.7)7 (46.7)0 (0)7 (46.7)
 Abdominal malignancy (n=9)2 (22.2)3 (33.3)0 (0)4 (44.4)
  • *P<0.05.